Levilactobacillus Brevis ibiome003 for Gut-Brain Axis Depression Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressant medications have significant side effects and varying clinical remission rates, with about 30% of patients not achieving remission, and existing probiotics like Lactobacillus brevis have unclear efficacy in treating depression.
Innovation Solution
The use of Levilactobacillus brevis ibiome003, preserved at the China Centre for Type Culture Collection, in formulations such as oral and injection preparations, combined with other bacteria or pharmaceutically active ingredients, to treat depression and anxiety, with a dosage of 10^7 to 10^12 CFU and administration methods including intramuscular, intravenous, and oral routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antidepressant medications act on monoamine neurotransmitter by increasing content in synaptic cleft, then mood improvement and depressive symptom relief are achieved, but significant side effects including headache, dizziness, gastrointestinal discomfort, sexual dysfunction, and addiction occur
Solution Approach 1:
The patent introduces probiotics (specifically Lactobacillus brevis, Bifidobacterium longum, and their combinations) as intermediary substances that act on the gut-brain axis to treat depression. Instead of directly acting on monoamine neurotransmitters in the brain, the probiotics modify gut microbiota composition, which then influences brain function through the gut-brain axis, thereby achieving antidepressant effects while avoiding direct central nervous system side effects
Solution Approach 2:
The patent replaces the traditional pharmacological mechanism (direct chemical action on brain neurotransmitters) with a biological mechanism (probiotic modulation of gut microbiota). This substitution shifts the treatment approach from direct CNS intervention to indirect modulation through the gut-brain axis, reducing harmful effects while maintaining therapeutic efficacy
2Reliability
If antidepressant medications are administered to patients, then depressive symptoms are treated, but about 30% of patients cannot achieve remission and clinical remission rates vary significantly
Solution Approach 1:
The patent changes the fundamental parameter of treatment from direct neurotransmitter modulation to gut microbiota composition modification. By targeting different bacterial strains (Lactobacillus brevis, Bifidobacterium longum, and their combinations) and administering them in specific formulations, the treatment adapts to individual patients' gut microbiota profiles, potentially improving remission rates and reducing variability in response
Solution Approach 2:
The patent uses composite probiotic formulations containing multiple bacterial strains (Lactobacillus brevis and Bifidobacterium longum together) to achieve synergistic effects. This composite approach may address the limitations of single-strain treatments and improve overall efficacy and adaptability across different patient populations
3Reliability
If Lactobacillus brevis is used to produce GABA to relieve anxiety and improve sleep, then anxiolytic and sleep-promoting effects are achieved, but the efficacy for treating depression remains unclear
Solution Approach 1:
The patent demonstrates that the probiotic formulation (Lactobacillus brevis, Bifidobacterium longum, or their combinations) possesses multiple functions: it not only produces GABA for anxiolytic and sleep-promoting effects but also effectively treats depression. The same probiotic preparation shows efficacy across multiple psychiatric conditions, establishing its universality and filling the knowledge gap regarding depression treatment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Levilactobacillus brevis ibiome003 effectively alleviates depressive-like behaviors in various models, including chronic stress, amino acid diet-induced, and corticosterone-induced depression in mice, without adverse effects on weight or internal organs, and demonstrates high colonization efficiency and acid and bile salt resistance.
Implementation Method 1
Lactobacillus brevis (Levilactobacillus brevis used as the name) has excellent GABA production ability
Implementation Method 2
Brain-gut axis is composed of complex reflection network including central nervous system (CNS), neuroendocrine system, neuroimmune system, the sympathetic nerve and parasympathetic nerve of the autonomous nervous system (ANS), enteric nervous system (ENS), and a composed of gut microbiota
Data Source
Figure 1~2
Figure 3
Figure 4A~4C
AI summary
Provided is a Levilactobacillus brevis ibiome003, and further provided are a pharmaceutical composition, a microbial agent composition and a food composition containing the strain. It is found that the microbial agent can effectively prevent, treat and relieve depression caused by various reasons.